Hoping To Smooth Relations With FDA, Sarepta Moves On From CEO Garabedian
This article was originally published in The Pink Sheet Daily
Executive Summary
Seeing Garabedian’s relationship with FDA as strained, Sarepta promotes Chief Medical Officer to interim CEO post in hopes of keeping eteplirsen on track for a mid-year NDA filing.